nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—SLC19A1—gonad—brain cancer	0.0172	0.0654	CbGeAlD
Pralatrexate—DHFR—E2F transcription factor network—HIC1—brain cancer	0.0145	0.04	CbGpPWpGaD
Pralatrexate—TYMS—Podofilox—Etoposide—brain cancer	0.0139	1	CbGdCrCtD
Pralatrexate—SLC19A1—endocrine gland—brain cancer	0.013	0.0494	CbGeAlD
Pralatrexate—SLC19A1—head—brain cancer	0.0128	0.0488	CbGeAlD
Pralatrexate—TYMS—E2F transcription factor network—HIC1—brain cancer	0.0126	0.0349	CbGpPWpGaD
Pralatrexate—Neoplasm malignant—Procarbazine—brain cancer	0.0123	0.0339	CcSEcCtD
Pralatrexate—SLC19A1—central nervous system—brain cancer	0.0117	0.0446	CbGeAlD
Pralatrexate—SLC19A1—cerebellum—brain cancer	0.0114	0.0435	CbGeAlD
Pralatrexate—FPGS—pituitary gland—brain cancer	0.0112	0.0425	CbGeAlD
Pralatrexate—FPGS—medulla oblongata—brain cancer	0.0108	0.041	CbGeAlD
Pralatrexate—Pancytopenia—Lomustine—brain cancer	0.00984	0.0271	CcSEcCtD
Pralatrexate—DHFR—G1/S-Specific Transcription—CCNE1—brain cancer	0.00981	0.0271	CbGpPWpGaD
Pralatrexate—FPGS—spinal cord—brain cancer	0.0096	0.0366	CbGeAlD
Pralatrexate—SLC19A1—brain—brain cancer	0.00928	0.0354	CbGeAlD
Pralatrexate—DHFR—One Carbon Metabolism—DNMT1—brain cancer	0.00922	0.0255	CbGpPWpGaD
Pralatrexate—SLC19A1—Folate Metabolism—SOD2—brain cancer	0.00909	0.0252	CbGpPWpGaD
Pralatrexate—TYMS—telencephalon—brain cancer	0.00899	0.0343	CbGeAlD
Pralatrexate—DHFR—telencephalon—brain cancer	0.0089	0.0339	CbGeAlD
Pralatrexate—DHFR—G1/S-Specific Transcription—PCNA—brain cancer	0.00869	0.024	CbGpPWpGaD
Pralatrexate—FPGS—endocrine gland—brain cancer	0.00864	0.0329	CbGeAlD
Pralatrexate—TYMS—G1/S-Specific Transcription—CCNE1—brain cancer	0.00856	0.0237	CbGpPWpGaD
Pralatrexate—FPGS—head—brain cancer	0.00853	0.0325	CbGeAlD
Pralatrexate—DHFR—Trans-sulfuration and one carbon metabolism—DNMT1—brain cancer	0.00828	0.0229	CbGpPWpGaD
Pralatrexate—TYMS—One Carbon Metabolism—DNMT1—brain cancer	0.00804	0.0222	CbGpPWpGaD
Pralatrexate—FPGS—central nervous system—brain cancer	0.00779	0.0297	CbGeAlD
Pralatrexate—FPGS—cerebellum—brain cancer	0.00761	0.029	CbGeAlD
Pralatrexate—TYMS—G1/S-Specific Transcription—PCNA—brain cancer	0.00758	0.021	CbGpPWpGaD
Pralatrexate—TYMS—gonad—brain cancer	0.0075	0.0286	CbGeAlD
Pralatrexate—DHFR—gonad—brain cancer	0.00743	0.0283	CbGeAlD
Pralatrexate—DHFR—pituitary gland—brain cancer	0.00725	0.0276	CbGeAlD
Pralatrexate—TYMS—Trans-sulfuration and one carbon metabolism—DNMT1—brain cancer	0.00723	0.02	CbGpPWpGaD
Pralatrexate—DHFR—medulla oblongata—brain cancer	0.00699	0.0267	CbGeAlD
Pralatrexate—Toxic epidermal necrolysis—Procarbazine—brain cancer	0.00685	0.0189	CcSEcCtD
Pralatrexate—Leukopenia—Lomustine—brain cancer	0.00646	0.0178	CcSEcCtD
Pralatrexate—TYMS—midbrain—brain cancer	0.00646	0.0246	CbGeAlD
Pralatrexate—DHFR—midbrain—brain cancer	0.00639	0.0244	CbGeAlD
Pralatrexate—Pancytopenia—Procarbazine—brain cancer	0.00624	0.0172	CcSEcCtD
Pralatrexate—DHFR—spinal cord—brain cancer	0.00624	0.0238	CbGeAlD
Pralatrexate—FPGS—brain—brain cancer	0.00618	0.0236	CbGeAlD
Pralatrexate—DHFR—E2F mediated regulation of DNA replication—CCNE1—brain cancer	0.00577	0.016	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Lomustine—brain cancer	0.00577	0.0159	CcSEcCtD
Pralatrexate—Sepsis—Carmustine—brain cancer	0.00569	0.0157	CcSEcCtD
Pralatrexate—TYMS—endocrine gland—brain cancer	0.00567	0.0216	CbGeAlD
Pralatrexate—DHFR—endocrine gland—brain cancer	0.00561	0.0214	CbGeAlD
Pralatrexate—Anorexia—Lomustine—brain cancer	0.00561	0.0155	CcSEcCtD
Pralatrexate—TYMS—head—brain cancer	0.0056	0.0213	CbGeAlD
Pralatrexate—DHFR—head—brain cancer	0.00554	0.0211	CbGeAlD
Pralatrexate—Epistaxis—Procarbazine—brain cancer	0.00553	0.0153	CcSEcCtD
Pralatrexate—Body temperature increased—Carboplatin—brain cancer	0.00532	0.0147	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—RELA—brain cancer	0.00526	0.0145	CbGpPWpGaD
Pralatrexate—Decreased appetite—Lomustine—brain cancer	0.00512	0.0141	CcSEcCtD
Pralatrexate—DHFR—E2F mediated regulation of DNA replication—PCNA—brain cancer	0.00511	0.0141	CbGpPWpGaD
Pralatrexate—TYMS—central nervous system—brain cancer	0.00511	0.0195	CbGeAlD
Pralatrexate—DHFR—central nervous system—brain cancer	0.00506	0.0193	CbGeAlD
Pralatrexate—TYMS—E2F mediated regulation of DNA replication—CCNE1—brain cancer	0.00503	0.0139	CbGpPWpGaD
Pralatrexate—TYMS—cerebellum—brain cancer	0.00499	0.019	CbGeAlD
Pralatrexate—DHFR—cerebellum—brain cancer	0.00494	0.0188	CbGeAlD
Pralatrexate—Pancytopenia—Hydroxyurea—brain cancer	0.00483	0.0133	CcSEcCtD
Pralatrexate—Neutropenia—Hydroxyurea—brain cancer	0.00476	0.0131	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—IL2—brain cancer	0.00473	0.0131	CbGpPWpGaD
Pralatrexate—Body temperature increased—Lomustine—brain cancer	0.00466	0.0129	CcSEcCtD
Pralatrexate—FPGS—Fluoropyrimidine Activity—TP53—brain cancer	0.0045	0.0124	CbGpPWpGaD
Pralatrexate—TYMS—E2F mediated regulation of DNA replication—PCNA—brain cancer	0.00446	0.0123	CbGpPWpGaD
Pralatrexate—Sepsis—Etoposide—brain cancer	0.0044	0.0121	CcSEcCtD
Pralatrexate—Liver function test abnormal—Carmustine—brain cancer	0.00439	0.0121	CcSEcCtD
Pralatrexate—Hypokalaemia—Carmustine—brain cancer	0.00433	0.012	CcSEcCtD
Pralatrexate—Dehydration—Temozolomide—brain cancer	0.00428	0.0118	CcSEcCtD
Pralatrexate—Anaemia—Procarbazine—brain cancer	0.00423	0.0117	CcSEcCtD
Pralatrexate—Hypokalaemia—Temozolomide—brain cancer	0.00419	0.0116	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Temozolomide—brain cancer	0.00414	0.0114	CcSEcCtD
Pralatrexate—Leukopenia—Procarbazine—brain cancer	0.0041	0.0113	CcSEcCtD
Pralatrexate—TYMS—brain—brain cancer	0.00406	0.0155	CbGeAlD
Pralatrexate—DHFR—brain—brain cancer	0.00402	0.0153	CbGeAlD
Pralatrexate—Cough—Procarbazine—brain cancer	0.004	0.011	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—SKP2—brain cancer	0.00396	0.0109	CbGpPWpGaD
Pralatrexate—Pancytopenia—Carmustine—brain cancer	0.00391	0.0108	CcSEcCtD
Pralatrexate—Neutropenia—Carmustine—brain cancer	0.00385	0.0106	CcSEcCtD
Pralatrexate—Pancytopenia—Temozolomide—brain cancer	0.00378	0.0104	CcSEcCtD
Pralatrexate—Vomiting—Lomustine—brain cancer	0.00374	0.0103	CcSEcCtD
Pralatrexate—Oedema—Procarbazine—brain cancer	0.00374	0.0103	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—DNMT1—brain cancer	0.00372	0.0103	CbGpPWpGaD
Pralatrexate—Neutropenia—Temozolomide—brain cancer	0.00372	0.0103	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Temozolomide—brain cancer	0.00369	0.0102	CcSEcCtD
Pralatrexate—Thrombocytopenia—Procarbazine—brain cancer	0.00366	0.0101	CcSEcCtD
Pralatrexate—Tachycardia—Procarbazine—brain cancer	0.00365	0.0101	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—NTRK3—brain cancer	0.00362	0.01	CbGpPWpGaD
Pralatrexate—Anorexia—Procarbazine—brain cancer	0.00356	0.00984	CcSEcCtD
Pralatrexate—SLC19A1—Disease—DTX2—brain cancer	0.00356	0.00986	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—CDK6—brain cancer	0.00353	0.00976	CbGpPWpGaD
Pralatrexate—Nausea—Lomustine—brain cancer	0.0035	0.00966	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—SKP2—brain cancer	0.00345	0.00955	CbGpPWpGaD
Pralatrexate—Toxic epidermal necrolysis—Etoposide—brain cancer	0.00331	0.00915	CcSEcCtD
Pralatrexate—DHFR—G1/S Transition—SKP2—brain cancer	0.0033	0.00914	CbGpPWpGaD
Pralatrexate—Anaemia—Hydroxyurea—brain cancer	0.00328	0.00905	CcSEcCtD
Pralatrexate—Decreased appetite—Procarbazine—brain cancer	0.00325	0.00897	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—DNMT1—brain cancer	0.00325	0.00898	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—SOD2—brain cancer	0.00323	0.00894	CbGpPWpGaD
Pralatrexate—Fatigue—Procarbazine—brain cancer	0.00322	0.0089	CcSEcCtD
Pralatrexate—Constipation—Procarbazine—brain cancer	0.0032	0.00883	CcSEcCtD
Pralatrexate—Leukopenia—Hydroxyurea—brain cancer	0.00317	0.00876	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—SIRT1—brain cancer	0.0031	0.00856	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CDK6—brain cancer	0.00308	0.00852	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Procarbazine—brain cancer	0.00306	0.00844	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—CCNE1—brain cancer	0.00306	0.00846	CbGpPWpGaD
Pralatrexate—SLC19A1—Folate Metabolism—TP53—brain cancer	0.00304	0.00841	CbGpPWpGaD
Pralatrexate—FPGS—Disease—DTX2—brain cancer	0.00303	0.00838	CbGpPWpGaD
Pralatrexate—Pancytopenia—Etoposide—brain cancer	0.00302	0.00834	CcSEcCtD
Pralatrexate—Neutropenia—Etoposide—brain cancer	0.00297	0.00821	CcSEcCtD
Pralatrexate—Abdominal pain—Procarbazine—brain cancer	0.00296	0.00816	CcSEcCtD
Pralatrexate—Body temperature increased—Procarbazine—brain cancer	0.00296	0.00816	CcSEcCtD
Pralatrexate—Oedema—Hydroxyurea—brain cancer	0.00289	0.00799	CcSEcCtD
Pralatrexate—TYMS—G1/S Transition—SKP2—brain cancer	0.00288	0.00798	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Hydroxyurea—brain cancer	0.00283	0.00782	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—SKP2—brain cancer	0.00278	0.0077	CbGpPWpGaD
Pralatrexate—Back pain—Carmustine—brain cancer	0.00277	0.00765	CcSEcCtD
Pralatrexate—Anorexia—Hydroxyurea—brain cancer	0.00276	0.00761	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—SIRT1—brain cancer	0.0027	0.00747	CbGpPWpGaD
Pralatrexate—Asthenia—Procarbazine—brain cancer	0.00268	0.00741	CcSEcCtD
Pralatrexate—Back pain—Temozolomide—brain cancer	0.00268	0.0074	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—CCNE1—brain cancer	0.00267	0.00738	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—CCNE1—brain cancer	0.00266	0.00735	CbGpPWpGaD
Pralatrexate—Anaemia—Carmustine—brain cancer	0.00265	0.00731	CcSEcCtD
Pralatrexate—Pruritus—Procarbazine—brain cancer	0.00265	0.0073	CcSEcCtD
Pralatrexate—SLC19A1—Disease—HES5—brain cancer	0.00262	0.00724	CbGpPWpGaD
Pralatrexate—Dyspnoea—Hydroxyurea—brain cancer	0.00258	0.00712	CcSEcCtD
Pralatrexate—Leukopenia—Carmustine—brain cancer	0.00257	0.00708	CcSEcCtD
Pralatrexate—Anaemia—Temozolomide—brain cancer	0.00256	0.00707	CcSEcCtD
Pralatrexate—Diarrhoea—Procarbazine—brain cancer	0.00256	0.00706	CcSEcCtD
Pralatrexate—Decreased appetite—Hydroxyurea—brain cancer	0.00252	0.00694	CcSEcCtD
Pralatrexate—Fatigue—Hydroxyurea—brain cancer	0.00249	0.00689	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDK6—brain cancer	0.00248	0.00687	CbGpPWpGaD
Pralatrexate—Leukopenia—Temozolomide—brain cancer	0.00248	0.00684	CcSEcCtD
Pralatrexate—Constipation—Hydroxyurea—brain cancer	0.00247	0.00683	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—SKP2—brain cancer	0.00243	0.00672	CbGpPWpGaD
Pralatrexate—Cough—Temozolomide—brain cancer	0.00242	0.00667	CcSEcCtD
Pralatrexate—Vomiting—Procarbazine—brain cancer	0.00238	0.00656	CcSEcCtD
Pralatrexate—Rash—Procarbazine—brain cancer	0.00236	0.00651	CcSEcCtD
Pralatrexate—Dermatitis—Procarbazine—brain cancer	0.00236	0.0065	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—PCNA—brain cancer	0.00235	0.00651	CbGpPWpGaD
Pralatrexate—Oedema—Carmustine—brain cancer	0.00234	0.00646	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CCNE1—brain cancer	0.00232	0.00641	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Carmustine—brain cancer	0.00229	0.00632	CcSEcCtD
Pralatrexate—Body temperature increased—Hydroxyurea—brain cancer	0.00229	0.00631	CcSEcCtD
Pralatrexate—Tachycardia—Carmustine—brain cancer	0.00228	0.0063	CcSEcCtD
Pralatrexate—Oedema—Temozolomide—brain cancer	0.00226	0.00624	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—PPP1R12A—brain cancer	0.00225	0.00622	CbGpPWpGaD
Pralatrexate—Anorexia—Carmustine—brain cancer	0.00223	0.00616	CcSEcCtD
Pralatrexate—FPGS—Disease—HES5—brain cancer	0.00222	0.00615	CbGpPWpGaD
Pralatrexate—Nausea—Procarbazine—brain cancer	0.00222	0.00613	CcSEcCtD
Pralatrexate—DHFR—G1/S Transition—CCNE1—brain cancer	0.00222	0.00614	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Temozolomide—brain cancer	0.00221	0.00611	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDK6—brain cancer	0.00217	0.00599	CbGpPWpGaD
Pralatrexate—Anorexia—Temozolomide—brain cancer	0.00215	0.00595	CcSEcCtD
Pralatrexate—Back pain—Etoposide—brain cancer	0.00214	0.00592	CcSEcCtD
Pralatrexate—Dyspnoea—Carmustine—brain cancer	0.00209	0.00576	CcSEcCtD
Pralatrexate—Asthenia—Hydroxyurea—brain cancer	0.00208	0.00573	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—PCNA—brain cancer	0.00205	0.00568	CbGpPWpGaD
Pralatrexate—Anaemia—Etoposide—brain cancer	0.00205	0.00566	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—CDK4—brain cancer	0.00203	0.00563	CbGpPWpGaD
Pralatrexate—Decreased appetite—Carmustine—brain cancer	0.00203	0.00561	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—CYP2C9—brain cancer	0.00202	0.00558	CbGpPWpGaD
Pralatrexate—Dyspnoea—Temozolomide—brain cancer	0.00202	0.00556	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—PPP1R12A—brain cancer	0.00201	0.00557	CbGpPWpGaD
Pralatrexate—Constipation—Carmustine—brain cancer	0.002	0.00552	CcSEcCtD
Pralatrexate—Leukopenia—Etoposide—brain cancer	0.00198	0.00548	CcSEcCtD
Pralatrexate—Diarrhoea—Hydroxyurea—brain cancer	0.00198	0.00547	CcSEcCtD
Pralatrexate—DHFR—G1/S Transition—PCNA—brain cancer	0.00197	0.00544	CbGpPWpGaD
Pralatrexate—Decreased appetite—Temozolomide—brain cancer	0.00197	0.00542	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle, Mitotic—PPP1R12A—brain cancer	0.00196	0.00543	CbGpPWpGaD
Pralatrexate—Fatigue—Temozolomide—brain cancer	0.00195	0.00538	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	0.00194	0.00537	CbGpPWpGaD
Pralatrexate—TYMS—G1/S Transition—CCNE1—brain cancer	0.00194	0.00536	CbGpPWpGaD
Pralatrexate—Cough—Etoposide—brain cancer	0.00193	0.00534	CcSEcCtD
Pralatrexate—Constipation—Temozolomide—brain cancer	0.00193	0.00534	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Carmustine—brain cancer	0.00191	0.00528	CcSEcCtD
Pralatrexate—DHFR—Fluoropyrimidine Activity—TP53—brain cancer	0.00188	0.0052	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CCNE1—brain cancer	0.00187	0.00517	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—RELA—brain cancer	0.00187	0.00516	CbGpPWpGaD
Pralatrexate—Abdominal pain—Carmustine—brain cancer	0.00185	0.0051	CcSEcCtD
Pralatrexate—Body temperature increased—Carmustine—brain cancer	0.00185	0.0051	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Temozolomide—brain cancer	0.00185	0.0051	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	0.00184	0.00509	CbGpPWpGaD
Pralatrexate—Vomiting—Hydroxyurea—brain cancer	0.00184	0.00508	CcSEcCtD
Pralatrexate—Rash—Hydroxyurea—brain cancer	0.00182	0.00504	CcSEcCtD
Pralatrexate—Dermatitis—Hydroxyurea—brain cancer	0.00182	0.00503	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—CDKN2A—brain cancer	0.00179	0.00495	CbGpPWpGaD
Pralatrexate—Abdominal pain—Temozolomide—brain cancer	0.00179	0.00493	CcSEcCtD
Pralatrexate—Body temperature increased—Temozolomide—brain cancer	0.00179	0.00493	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CDK4—brain cancer	0.00178	0.00491	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Etoposide—brain cancer	0.00177	0.00489	CcSEcCtD
Pralatrexate—Tachycardia—Etoposide—brain cancer	0.00177	0.00487	CcSEcCtD
Pralatrexate—SLC19A1—Disease—IDH1—brain cancer	0.00176	0.00487	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—PPP1R12A—brain cancer	0.00176	0.00486	CbGpPWpGaD
Pralatrexate—Anorexia—Etoposide—brain cancer	0.00172	0.00476	CcSEcCtD
Pralatrexate—Nausea—Hydroxyurea—brain cancer	0.00172	0.00474	CcSEcCtD
Pralatrexate—TYMS—G1/S Transition—PCNA—brain cancer	0.00171	0.00474	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CYP2C9—brain cancer	0.00171	0.00474	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—BSG—brain cancer	0.00171	0.00474	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—IL2—brain cancer	0.00168	0.00465	CbGpPWpGaD
Pralatrexate—Asthenia—Carmustine—brain cancer	0.00168	0.00463	CcSEcCtD
Pralatrexate—SLC19A1—Disease—HEY1—brain cancer	0.00167	0.00462	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—PCNA—brain cancer	0.00166	0.00458	CbGpPWpGaD
Pralatrexate—TYMS—Fluoropyrimidine Activity—TP53—brain cancer	0.00164	0.00454	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—DLL1—brain cancer	0.00164	0.00453	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CCNE1—brain cancer	0.00163	0.00451	CbGpPWpGaD
Pralatrexate—Asthenia—Temozolomide—brain cancer	0.00162	0.00448	CcSEcCtD
Pralatrexate—Dyspnoea—Etoposide—brain cancer	0.00161	0.00445	CcSEcCtD
Pralatrexate—Diarrhoea—Carmustine—brain cancer	0.0016	0.00442	CcSEcCtD
Pralatrexate—Pruritus—Temozolomide—brain cancer	0.0016	0.00441	CcSEcCtD
Pralatrexate—Decreased appetite—Etoposide—brain cancer	0.00157	0.00434	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—CDKN2A—brain cancer	0.00156	0.00432	CbGpPWpGaD
Pralatrexate—Fatigue—Etoposide—brain cancer	0.00156	0.00431	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	0.00155	0.0043	CbGpPWpGaD
Pralatrexate—Constipation—Etoposide—brain cancer	0.00155	0.00427	CcSEcCtD
Pralatrexate—Diarrhoea—Temozolomide—brain cancer	0.00155	0.00427	CcSEcCtD
Pralatrexate—FPGS—Disease—IDH1—brain cancer	0.0015	0.00414	CbGpPWpGaD
Pralatrexate—Vomiting—Carmustine—brain cancer	0.00149	0.00411	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Etoposide—brain cancer	0.00148	0.00408	CcSEcCtD
Pralatrexate—Rash—Carmustine—brain cancer	0.00147	0.00407	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—IDH1—brain cancer	0.00147	0.00408	CbGpPWpGaD
Pralatrexate—Dermatitis—Carmustine—brain cancer	0.00147	0.00407	CcSEcCtD
Pralatrexate—FPGS—Metabolism—BSG—brain cancer	0.00146	0.00403	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—PCNA—brain cancer	0.00145	0.004	CbGpPWpGaD
Pralatrexate—Vomiting—Temozolomide—brain cancer	0.00144	0.00397	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDK4—brain cancer	0.00143	0.00396	CbGpPWpGaD
Pralatrexate—Body temperature increased—Etoposide—brain cancer	0.00143	0.00395	CcSEcCtD
Pralatrexate—Abdominal pain—Etoposide—brain cancer	0.00143	0.00395	CcSEcCtD
Pralatrexate—Rash—Temozolomide—brain cancer	0.00143	0.00393	CcSEcCtD
Pralatrexate—Dermatitis—Temozolomide—brain cancer	0.00142	0.00393	CcSEcCtD
Pralatrexate—FPGS—Disease—HEY1—brain cancer	0.00142	0.00393	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ENO2—brain cancer	0.00139	0.00385	CbGpPWpGaD
Pralatrexate—FPGS—Disease—DLL1—brain cancer	0.00139	0.00385	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—SHH—brain cancer	0.00139	0.00385	CbGpPWpGaD
Pralatrexate—Nausea—Carmustine—brain cancer	0.00139	0.00384	CcSEcCtD
Pralatrexate—Nausea—Temozolomide—brain cancer	0.00134	0.00371	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—CCND1—brain cancer	0.00131	0.00363	CbGpPWpGaD
Pralatrexate—Asthenia—Etoposide—brain cancer	0.0013	0.00358	CcSEcCtD
Pralatrexate—Pruritus—Etoposide—brain cancer	0.00128	0.00353	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	0.00128	0.00353	CbGpPWpGaD
Pralatrexate—DHFR—Disease—DTX2—brain cancer	0.00127	0.0035	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—IDH1—brain cancer	0.00125	0.00347	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	0.00125	0.00346	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDK4—brain cancer	0.00125	0.00346	CbGpPWpGaD
Pralatrexate—Diarrhoea—Etoposide—brain cancer	0.00124	0.00342	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	0.00124	0.00342	CbGpPWpGaD
Pralatrexate—DHFR—E2F transcription factor network—MYC—brain cancer	0.00121	0.00335	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—SIRT1—brain cancer	0.0012	0.00332	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ENO2—brain cancer	0.00118	0.00327	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SHH—brain cancer	0.00118	0.00327	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ENO2—brain cancer	0.00117	0.00322	CbGpPWpGaD
Pralatrexate—Vomiting—Etoposide—brain cancer	0.00115	0.00317	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	0.00115	0.00318	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CCND1—brain cancer	0.00115	0.00317	CbGpPWpGaD
Pralatrexate—Rash—Etoposide—brain cancer	0.00114	0.00315	CcSEcCtD
Pralatrexate—Dermatitis—Etoposide—brain cancer	0.00114	0.00315	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	0.00109	0.00303	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN2A—brain cancer	0.00109	0.00303	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—TP53—brain cancer	0.00108	0.00299	CbGpPWpGaD
Pralatrexate—Nausea—Etoposide—brain cancer	0.00107	0.00297	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—MYC—brain cancer	0.00106	0.00293	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—brain cancer	0.00105	0.00292	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—SKP2—brain cancer	0.00102	0.00283	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—VAV1—brain cancer	0.00101	0.00278	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ENO2—brain cancer	0.000991	0.00274	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN2A—brain cancer	0.000955	0.00264	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	0.000946	0.00262	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HES5—brain cancer	0.000929	0.00257	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CCND1—brain cancer	0.000924	0.00256	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MYC—brain cancer	0.00092	0.00254	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—SKP2—brain cancer	0.000913	0.00253	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDK6—brain cancer	0.00091	0.00252	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—CDK4—brain cancer	0.000908	0.00251	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—SKP2—brain cancer	0.000891	0.00247	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—APC—brain cancer	0.000891	0.00246	CbGpPWpGaD
Pralatrexate—DHFR—G1/S Transition—MYC—brain cancer	0.00088	0.00243	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—brain cancer	0.000865	0.00239	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HES1—brain cancer	0.000865	0.00239	CbGpPWpGaD
Pralatrexate—FPGS—Disease—VAV1—brain cancer	0.000855	0.00236	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PDGFRA—brain cancer	0.000823	0.00228	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDK6—brain cancer	0.000814	0.00225	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CCND1—brain cancer	0.000807	0.00223	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—SKP2—brain cancer	0.000797	0.0022	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDK6—brain cancer	0.000794	0.0022	CbGpPWpGaD
Pralatrexate—TYMS—G1/S Transition—MYC—brain cancer	0.000768	0.00212	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—brain cancer	0.000755	0.00209	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—MYC—brain cancer	0.000741	0.00205	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HES1—brain cancer	0.000735	0.00203	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—IRS2—brain cancer	0.000723	0.002	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP2C9—brain cancer	0.000716	0.00198	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDK6—brain cancer	0.00071	0.00197	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PDGFRA—brain cancer	0.0007	0.00194	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	0.000692	0.00191	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCNE1—brain cancer	0.000686	0.0019	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—MYC—brain cancer	0.000647	0.00179	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—APC—brain cancer	0.000638	0.00177	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—BRCA2—brain cancer	0.000633	0.00175	CbGpPWpGaD
Pralatrexate—DHFR—Disease—IDH1—brain cancer	0.000625	0.00173	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP2C9—brain cancer	0.000625	0.00173	CbGpPWpGaD
Pralatrexate—FPGS—Disease—IRS2—brain cancer	0.000614	0.0017	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCNE1—brain cancer	0.000613	0.0017	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	0.000611	0.00169	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—BSG—brain cancer	0.000609	0.00168	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—PCNA—brain cancer	0.000607	0.00168	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	0.000605	0.00167	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCNE1—brain cancer	0.000598	0.00166	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HEY1—brain cancer	0.000593	0.00164	CbGpPWpGaD
Pralatrexate—DHFR—Disease—DLL1—brain cancer	0.000581	0.00161	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—BRCA2—brain cancer	0.000552	0.00153	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—PCNA—brain cancer	0.000543	0.0015	CbGpPWpGaD
Pralatrexate—FPGS—Disease—APC—brain cancer	0.000543	0.0015	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCNE1—brain cancer	0.000535	0.00148	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CG—brain cancer	0.000535	0.00148	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	0.000533	0.00147	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—BSG—brain cancer	0.000531	0.00147	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—PCNA—brain cancer	0.00053	0.00147	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDK4—brain cancer	0.000525	0.00145	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—IDH1—brain cancer	0.000524	0.00145	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ERBB2—brain cancer	0.000496	0.00137	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SHH—brain cancer	0.000494	0.00137	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ENO2—brain cancer	0.000494	0.00137	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	0.00049	0.00136	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	0.000479	0.00133	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—PCNA—brain cancer	0.000474	0.00131	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDK4—brain cancer	0.000469	0.0013	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDK4—brain cancer	0.000458	0.00127	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—IDH1—brain cancer	0.000457	0.00126	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CG—brain cancer	0.000454	0.00126	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CTNNB1—brain cancer	0.000434	0.0012	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ERBB2—brain cancer	0.000421	0.00117	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ENO2—brain cancer	0.000414	0.00115	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDK4—brain cancer	0.00041	0.00113	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	0.000403	0.00111	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—brain cancer	0.000401	0.00111	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—brain cancer	0.000386	0.00107	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—STAT3—brain cancer	0.000378	0.00105	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CTNNB1—brain cancer	0.000369	0.00102	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ENO2—brain cancer	0.000361	0.000999	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN2A—brain cancer	0.000359	0.000993	CbGpPWpGaD
Pralatrexate—DHFR—Disease—VAV1—brain cancer	0.000357	0.000988	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MYC—brain cancer	0.000351	0.000972	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN2A—brain cancer	0.00035	0.000969	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EGFR—brain cancer	0.000344	0.00095	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCND1—brain cancer	0.000339	0.000938	CbGpPWpGaD
Pralatrexate—FPGS—Disease—STAT3—brain cancer	0.000321	0.000889	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN2A—brain cancer	0.000313	0.000866	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HES1—brain cancer	0.000307	0.00085	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCND1—brain cancer	0.000303	0.000839	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MYC—brain cancer	0.000299	0.000826	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCND1—brain cancer	0.000296	0.000819	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PDGFRA—brain cancer	0.000292	0.000809	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EGFR—brain cancer	0.000292	0.000808	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MYC—brain cancer	0.000272	0.000752	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCND1—brain cancer	0.000265	0.000732	CbGpPWpGaD
Pralatrexate—DHFR—Disease—IRS2—brain cancer	0.000257	0.00071	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MYC—brain cancer	0.000243	0.000673	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MYC—brain cancer	0.000237	0.000657	CbGpPWpGaD
Pralatrexate—DHFR—Disease—APC—brain cancer	0.000227	0.000627	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MYC—brain cancer	0.000212	0.000587	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—brain cancer	0.0002	0.000553	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CG—brain cancer	0.00019	0.000525	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERBB2—brain cancer	0.000176	0.000487	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—brain cancer	0.000174	0.000482	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CG—brain cancer	0.000166	0.000458	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CTNNB1—brain cancer	0.000154	0.000426	CbGpPWpGaD
Pralatrexate—DHFR—Disease—STAT3—brain cancer	0.000134	0.000371	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MYC—brain cancer	0.000125	0.000345	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EGFR—brain cancer	0.000122	0.000338	CbGpPWpGaD
